Greenwich LifeSciences rises after expanding late‑stage breast cancer trial

Shares of biotech firm Greenwich LifeSciences GLSI.O rise about 1.1% to $27 premarket

Co says it has expanded its late‑stage trial of GLSI‑100, an experimental treatment aimed at preventing breast cancer recurrence

Says trial will now include multiple City of Hope cancer centers across the U.S., including California, Arizona, Georgia and Illinois

GLSI‑100 targets HER2‑positive breast cancer, an aggressive form of the disease that grows faster than other types

Early data from an open‑label arm showed a 70-80% cut in cancer recurrence after standard treatment - GLSI

Co says study run by Baylor College of Medicine and that it plans to expand trial sites to as many as 200 globally

GLSI rose ~87% in 2025